AlphAIAlphAI — Financial news for AI agents
investing.comOCT 122 min read$BMRN

Raymond James upgrades BioMarin stock to strong buy on valuation

Raymond James upgraded BioMarin (BMRN) to Strong Buy with a $109 price target, citing undervaluation and strong growth prospects. The stock trades at $54.80, down 7.8% YTD. Other analysts have mixed views, with price targets ranging from $60 to $97. BioMarin also discontinued Voxzogo development for Noonan syndrome.

Original reporting
investing.com
Published Oct 12, 2026, 9:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BMRN
Bullish
high confidence
Mentioned
$BMRN
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMRNBullishMed
01

Why it matters

The upgrade provides a new actionable catalyst, while the product discontinuation and settlement may temper upside.

02

Market read

Analyst upgrade to Strong Buy could drive short‑term buying interest in BMRN.

03

What to watch

Potential revenue loss from the discontinued Voxzogo program and ongoing patent disputes.

Relevance 6/10Novelty 6/10Timing: today

Background

The article reports an analyst upgrade and price‑target changes for BioMarin, along with recent product and legal updates.

Company-level read

Ticker impact

$BMRNBullishHigh confidence
Context

Raymond James upgraded BioMarin Pharmaceutical to Strong Buy with a $109 price target, citing valuation and growth prospects.

Expected impact

likely upward pressure as investors price in the higher $109 target.

Evidence & confidence

The upgrade is a fresh, primary analyst action with a specific price target, providing a clear catalyst for buying.

Market effects

Sector

May lift sentiment in the rare‑disease biotech sector as peers could be re‑rated.

Regional

Limited to U.S. biotech investors; no broader market effect.

Global

Minimal global impact beyond sector.

Counterpoint

What could challenge this read

The upgrade may be premature given recent product discontinuation and competitive pressures.

Key entities

  • company
    BioMarin Pharmaceutical Inc.

    US‑listed biotech focused on rare diseases.

  • analyst_firm
    Raymond James

    Equity research firm issuing the upgrade.

Read at source← All news

Related articles

OCT 16
$BMRNMed

BioMarin Stock Surges As Wall Street Redraws The Map

BioMarin Pharmaceutical (BMRN) shares rose following a Buy rating from UBS, which cited undervaluation relative to 2027 earnings. The FDA submission for Voxzogo's label expansion and positive clinical data also boosted investor confidence. The company's revenue growth and higher guidance indicate traction in rare-disease drugs, but margin pressure and acquisition financing costs remain concerns.

tipranks.com2 min
OCT 9
$BMRNMedAI 8/10

BioMarin to present data on achondroplasia treatment at ASBMR

BioMarin Pharmaceutical Inc. (BMRN) will present data from 13 studies at the ASBMR 2026 Annual Meeting, including new imaging results for VOXZOGO in treating achondroplasia. The company submitted a supplemental NDA for VOXZOGO to treat hypochondroplasia and expects a 2027 launch if approved. BioMarin also announced data on BMN 333 and BMN 401. VOXZOGO is currently approved in the U.S., Japan, and Australia for achondroplasia.

investing.com1 min
OCT 9
$BMRNMed

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Pharmaceutical Inc. (BMRN) presented new data at the American Society for Bone and Mineral Research 2026 Annual Meeting, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The data showed encouraging imaging results from a trial evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia.

prnewswire.com2 min
OCT 6
$BMRNMed

BIOMARIN PHARMACEUTICAL INC (BMRN): Results of Operations and Financial Condition

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),

SEC EDGAR 8-K2 min